Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulka Vaishampayan

Showing results (71-80 of 176) with videos related to

Pageof 18
Sort By:
Journal of Kidney Cancer and VHL|November 12, 2020
Adrenal Metastases as Sanctuary Sites in Advanced Renal CancerUlka Vaishampayan, Harsh Shah, Mohammad F Asad, et al.
Investigational New Drugs|November 29, 2021
A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancerCorinne Maurice-Dror, Ronan Le Moigne, Ulka Vaishampayan, et al.
Anticancer Research|February 4, 2019
Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single InstitutionAmmar Sukari, Misako Nagasaka, Roba Alhasan, et al.
Kidney Cancer (Clifton, Va.)|March 12, 2019
Randomized Phase 2 Study of Trebananib (AMG 386) with or without Continued Anti-Vascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib - Results of NCI/CTEP Protocol 9048Thomas J Semrad, Susan Groshen, Chunqiao Luo, et al.
Journal of Vascular and Interventional Radiology : JVIR|April 28, 2012
Percutaneous cryoablation of metastatic renal cell carcinoma for local tumor control: feasibility, outcomes, and estimated cost-effectiveness for palliationHyun J Bang, Peter J Littrup, Dylan J Goodrich, et al.
Clinical Genitourinary Cancer|July 30, 2013
A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancerRoberto Pili, Rui Qin, P J Flynn, et al.
Investigational New Drugs|July 22, 2005
A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancerBasil F El-Rayes, Mark M Zalupski, Anthony F Shields, et al.
Nutrition and Cancer|October 7, 2010
Soy isoflavones in conjunction with radiation therapy in patients with prostate cancerIftekhar U Ahmad, Jeffrey D Forman, Fazlul H Sarkar, et al.
Urologic Oncology|February 17, 2019
Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancerAndrew W Hahn, David D Stenehjem, Anitha B Alex, et al.
Oncogene|August 17, 2018
A novel cross-talk between CXCR4 and PI4KIIIα in prostate cancer cellsDiego Sbrissa, Louie Semaan, Barani Govindarajan, et al.
Pageof 18

Showing results (71-80 of 176) with videos related to

Sort By:
Pageof 18
Journal of Kidney Cancer and VHL|November 12, 2020
Adrenal Metastases as Sanctuary Sites in Advanced Renal CancerUlka Vaishampayan, Harsh Shah, Mohammad F Asad, et al.
Investigational New Drugs|November 29, 2021
A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancerCorinne Maurice-Dror, Ronan Le Moigne, Ulka Vaishampayan, et al.
Anticancer Research|February 4, 2019
Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single InstitutionAmmar Sukari, Misako Nagasaka, Roba Alhasan, et al.
Kidney Cancer (Clifton, Va.)|March 12, 2019
Randomized Phase 2 Study of Trebananib (AMG 386) with or without Continued Anti-Vascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib - Results of NCI/CTEP Protocol 9048Thomas J Semrad, Susan Groshen, Chunqiao Luo, et al.
Journal of Vascular and Interventional Radiology : JVIR|April 28, 2012
Percutaneous cryoablation of metastatic renal cell carcinoma for local tumor control: feasibility, outcomes, and estimated cost-effectiveness for palliationHyun J Bang, Peter J Littrup, Dylan J Goodrich, et al.
Clinical Genitourinary Cancer|July 30, 2013
A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancerRoberto Pili, Rui Qin, P J Flynn, et al.
Investigational New Drugs|July 22, 2005
A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancerBasil F El-Rayes, Mark M Zalupski, Anthony F Shields, et al.
Nutrition and Cancer|October 7, 2010
Soy isoflavones in conjunction with radiation therapy in patients with prostate cancerIftekhar U Ahmad, Jeffrey D Forman, Fazlul H Sarkar, et al.
Urologic Oncology|February 17, 2019
Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancerAndrew W Hahn, David D Stenehjem, Anitha B Alex, et al.
Oncogene|August 17, 2018
A novel cross-talk between CXCR4 and PI4KIIIα in prostate cancer cellsDiego Sbrissa, Louie Semaan, Barani Govindarajan, et al.
Pageof 18